Linked Life Data

3825736

Source:http://linkedlifedata.com/resource/pubmed/id/3825736

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1987-4-13
pubmed:abstractText
Marked improvement of the clinical state owing to CI 201-678 treatment was seen in six patients; no definite improvement was achieved in three patients. Daily fluctuations were improved in two patients. CI 201-678 demonstrated a good effect against rigidity, impairment of gait and posture, as well as impaired self-care, although daily levodopa dosage was concomitantly reduced. In two patients, CI 201-678 was discontinued because of side-effects, while one patient stopped treatment for reasons not related to the drug. In contrast to apomorphine and other dopamimetic substances, the emetic side-effect of CI 201-678 is minimal (nausea in one patient). no arterial hypotension was not seen. It has to be mentioned that the two drug-related drop-outs were receiving CI 201-678 in a rapidly increasing dosage. It is likely that the side-effects would have been less pronounced if the dosage had been more slowly increased. However, the preliminary results indicate that CI 201-678 is a promising substance for the treatment of patients with predominant rigid-akinetic symptomatology, in combination with levodopa therapy or in the place of levodopa.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0091-3952
pubmed:author
pubmed:issnType
Print
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
591-2
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Therapeutic experiences with an abeorphine derivative in Parkinson's disease.
pubmed:publicationType
Journal Article